Every 10-Q that Kiniksa Pharmaceuticals International, plc (KNSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KNSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KNSA filings page.
Kiniksa Pharmaceuticals International, plc reported higher profitability for the three and six months ended June 30, 2026, driven by growth in ARCALYST. Product revenue, net was $243,600 for the quarter, up from $156,797 a year earlier, and $457,866 for the first half of 2026 versus $294,582 in 2025. Quarterly net income was $25,432 and first-half net income was $48,024, with diluted net income per share of $0.30 and $0.58, respectively.
As of June 30, 2026, cash and cash equivalents were $175,677 and short-term investments were $350,251, contributing to total assets of $896,110 and shareholders’ equity of $654,149. Management states that existing cash, cash equivalents and short-term investments, together with expected cash inflows from operations, are expected to fund operating expenses and capital expenditure requirements for at least the next 12 months. The company continues to advance its pipeline, including KPL-387, now in a pivotal Phase 3 recurrent pericarditis trial with expected commercialization in 2028 or 2029, and KPL-1161, for which a Phase 1 trial is planned by the end of 2026, while it has discontinued abiprubart development in Sjogren's Disease and is exploring strategic alternatives for that asset.
Kiniksa Pharmaceuticals International reported strong growth for the quarter ended March 31, 2026, driven by ARCALYST. Product revenue rose to $214.3 million, up from $137.8 million a year earlier, as more patients started treatment.
Net income increased to $22.6 million from $8.5 million, with diluted earnings per share rising to $0.27. Operating cash flow reached $50.2 million, and cash, cash equivalents and short-term investments totaled about $468.1 million, supporting ongoing R&D and commercialization.
The company continues to advance cardiovascular-focused programs, including KPL-387 in a Phase 2/3 trial for recurrent pericarditis and preclinical KPL-1161, while development of abiprubart has been discontinued as it explores strategic alternatives for that asset.
Kiniksa Pharmaceuticals International (KNSA) reported a profitable quarter. For Q3 2025, total revenue was $180.855 million, up from $112.214 million a year ago, driven entirely by higher net product revenue from ARCALYST in the U.S. Net income reached $18.435 million versus a loss of $12.693 million last year; diluted EPS was $0.23.
Operating expenses reflected ARCALYST profit sharing with Regeneron, with collaboration expenses at $63.307 million. Cost of goods sold was $20.257 million, R&D $24.166 million, and SG&A $49.104 million. Cash, cash equivalents and short‑term investments totaled $352.102 million as of September 30, 2025, and operating cash flow for the nine months was $84.091 million. Shareholders’ equity increased to $535.383 million from $438.436 million at year‑end.
Year‑to‑date, revenue was $475.437 million (vs. $300.703 million), with net income of $44.806 million (vs. a $34.305 million loss). The company terminated the mavrilimumab license with MedImmune effective May 22, 2025 and mutually terminated the Huadong mavrilimumab agreement; the ARCALYST Huadong agreement remains in place with $31.811 million recorded as non‑current deferred revenue.